Financial Performance - For the nine months ended September 30, 2022, the total revenue was RMB 57,171 million, an increase of 6.6% compared to RMB 53,753 million in the same period last year[5] - The gross profit for the same period was RMB 31,247 million, up from RMB 30,534 million, reflecting a gross margin improvement[5] - Operating profit for the three months ended September 30, 2022, was RMB 4,186 million, compared to RMB 1,753 million in the previous year, indicating a significant increase[5] - The net profit for the nine months ended September 30, 2022, was a loss of RMB 4,575 million, compared to a profit of RMB 2,146 million in the same period last year[5] - The total comprehensive income for the three months ended September 30, 2022, was a loss of RMB 454 million, compared to a gain of RMB 1,569 million in the same period last year[5] - The company reported a net loss attributable to shareholders of RMB 4,662,000 for the nine months ended September 30, 2022, compared to a profit of RMB 2,787,000 in the same period of 2021[44] - The group reported a loss attributable to owners of approximately RMB 4,662,000, with a loss per share of RMB 0.63, compared to earnings of RMB 2,787,000 and earnings per share of RMB 0.38 in the previous period[61] Revenue Breakdown - Revenue for the nine months ended September 30, 2022, was RMB 57,171,000, an increase of 6.9% from RMB 53,753,000 in the same period of 2021[36] - The revenue from funeral services and cremation services was RMB 54,352,000, up from RMB 51,065,000, representing a growth of 4.5%[35] - The geographical revenue breakdown shows that China accounted for 95.1% of total revenue, while Taiwan, Hong Kong, and Vietnam contributed 2.0%, 2.1%, and 0.8% respectively[51] - Revenue from the Chinese market was approximately RMB 54,352,000, an increase of about 4.9% compared to the previous period's RMB 51,798,000[53] - Revenue from cemetery sales in Vietnam increased by approximately 231.5% to RMB 484,000 from RMB 146,000 in the previous period[58] - Revenue from Taiwan increased by 9.6% to approximately RMB 1,145,000, while Hong Kong's revenue surged by approximately 55.8% to RMB 1,190,000 from RMB 764,000[56] Expenses and Costs - The company incurred administrative expenses of RMB 24,836 million for the nine months ended September 30, 2022, compared to RMB 20,128 million in the previous year[5] - The cost of sales increased by approximately 11.6% to RMB 25,924,000, consistent with revenue growth[59] - Administrative expenses rose by approximately 23.4% to RMB 24,836,000, accounting for 43.4% of revenue, compared to 37.4% in the previous period[61] Investments and Strategic Focus - The company has established a specialized investment platform focused on biotechnology, including biomedicine and life sciences instruments, to drive long-term strategic growth[48] - The group plans to allocate more resources to support the development of its biotechnology business and actively seek suitable investment opportunities to maximize investment income and shareholder returns[72] - The group is focused on investments in biotechnology, including biomedicine, healthcare, and life science instruments, to leverage synergies in emerging industries[70] - The group aims to expand its investment scale through equity and securities investments in the biotechnology sector[72] Corporate Governance and Compliance - The company has established an audit committee to oversee financial reporting procedures and internal control systems[94] - The audit committee, consisting of three independent non-executive directors, reviewed the group's unaudited consolidated financial statements for the period and confirmed compliance with applicable accounting standards[96] - The company faced delays in publishing its audited financial results for the year ended December 31, 2021, due to travel restrictions related to COVID-19, which constituted a failure to comply with GEM Listing Rules[93] Shareholder Information - As of September 30, 2022, Mr. Xu Jianchun holds 220,475,000 shares, representing approximately 29.69% of the issued share capital[74] - As of September 30, 2022, major shareholder Hong Kong Gaoqi holds 220,475,000 shares, also representing approximately 29.69% of the issued share capital[79] Operational Outlook - The board remains cautiously optimistic about the future of core businesses, including funeral services and life science instrument sales, while adopting a diversified operational strategy for sustainable development in 2022[72] - The group continues to monitor the impact of the COVID-19 pandemic on its financial condition and operational performance, ensuring proactive responses[72] - The group has not made any significant acquisitions or disposals during the period[66] Other Financial Information - The company did not declare any dividends for the current period, consistent with the previous period[46] - The company’s interest income from bank deposits decreased to RMB 173,000 from RMB 278,000, reflecting a decline of 37.9%[38] - The company’s financial assets generated income of RMB 2,948,000, which was not reported in the previous period[38] - Other income for the nine months ended September 30, 2022, was RMB 4,400,000, compared to RMB 1,569,000 in the same period of 2021, indicating a significant increase[38]

Financial Performance - The company's revenue for the six months ended June 30, 2022, was RMB 16,569 million, a decrease of 9.5% compared to RMB 18,310 million in the same period last year[6]. - Gross profit for the same period was RMB 8,596 million, down 18.7% from RMB 10,578 million year-on-year[6]. - The operating loss for the period was RMB 3,047 million, compared to an operating profit of RMB 1,260 million in the previous year[6]. - The net loss attributable to the company's owners was RMB 7,084 million, compared to a loss of RMB 312 million in the same period last year[10]. - The total comprehensive loss for the period was RMB 7,421 million, compared to a comprehensive income of RMB 239 million in the previous year[6]. - The total profit from external customers for the six months ended June 30, 2022, was RMB 5,814,000, down 33.5% from RMB 8,697,000 in the previous year[42]. - The company reported a pre-tax loss of RMB 1,436,000 for the six months ended June 30, 2022, compared to a profit of RMB 4,711,000 in the same period of 2021[42]. - The company reported a loss attributable to owners of RMB 6,362,000, compared to a profit of RMB 2,345,000 in the previous period[138]. Cash Flow and Assets - The company's cash and bank balances increased to RMB 125,138 million from RMB 117,557 million year-on-year[12]. - Non-current assets, including property, plant, and equipment, were valued at RMB 32,296 million, up from RMB 25,191 million in the previous year[12]. - The total assets less current liabilities amounted to RMB 146,422 million, compared to RMB 133,677 million in the previous year[12]. - The total cash and cash equivalents as of June 30, 2022, amounted to RMB 125,138,000, slightly down from RMB 125,616,000 at the beginning of the period[19]. - The cash and cash equivalents increased by RMB 8,059,000 during the six months ended June 30, 2022, compared to a decrease of RMB (815,000) in the same period of 2021[19]. - As of June 30, 2022, net trade receivables amounted to RMB 935,000, a 113% increase from RMB 439,000 as of December 31, 2021[94]. - The net amount of prepayments, deposits, and other receivables was RMB 30,072,000, a slight decrease from RMB 31,291,000[94]. Revenue Breakdown - Total revenue for the first half of 2022 was RMB 37,149,000, a slight decrease of 0.33% compared to RMB 37,271,000 in the same period of 2021[34]. - Revenue from funeral services and cremation services was RMB 35,061,000, down 1.30% from RMB 35,521,000 in the previous year[34]. - Revenue from funeral arrangements and related consulting services increased to RMB 1,482,000, up 34.55% from RMB 1,101,000 in the previous year[34]. - Sales of burial plots and tombstones rose to RMB 404,000, significantly up from RMB 144,000 in the previous year[34]. - Revenue from stem cell and immune cell consulting services decreased to RMB 202,000, down 60% from RMB 505,000 in the previous year[34]. - Revenue from the Chinese market was approximately RMB 35,061,000, a decrease of about 2.7% compared to the previous period's RMB 36,026,000[129]. - Revenue from Taiwan increased by 13.3% to approximately RMB 717,000, driven by fewer COVID-19 restrictions[132]. - Revenue from Hong Kong surged by approximately 106.6% to RMB 967,000, with new stem cell and immune cell consultation services generating RMB 202,000[132]. - Revenue from Vietnam rose significantly by 180.6% to RMB 404,000, attributed to the resumption of operations after previous lockdowns[134]. Expenses and Costs - Cost of sales increased by approximately 10.1% to RMB 17,136,000, primarily due to higher employee costs and one-time bonuses during the COVID-19 pandemic[135]. - Administrative expenses rose by approximately 39.1% to RMB 19,139,000, accounting for 51.5% of revenue, due to increased wage levels and special bonuses[137]. - Employee costs, including director remuneration, increased to RMB 15,640,000 from RMB 10,965,000, representing a rise of 42.5%[67]. - Financing costs decreased to RMB 982,000 from RMB 1,169,000, reflecting a reduction of 16%[42]. Investments and Financial Position - The group held financial assets measured at fair value totaling RMB 48,091,000 as of June 30, 2022, compared to RMB 38,577,000 as of December 31, 2021[89]. - The group held significant investments in equity securities listed outside Hong Kong amounting to RMB 15,082,000 as of June 30, 2022, compared to RMB 4,093,000 on December 31, 2021[146]. - The group recorded a net gain of approximately RMB 1,490,000 from realized and unrealized gains on financial assets measured at fair value during the period, compared to a net loss of RMB 37,000 in the previous period[92]. - The group has no significant acquisitions or disposals of investments during the reporting period[147]. Corporate Governance and Compliance - The financial statements are prepared in accordance with the GEM Listing Rules and Hong Kong Financial Reporting Standards[22]. - The board of directors has confirmed compliance with the corporate governance code as per GEM listing rules during the reporting period[191]. - An audit committee has been established, consisting of three independent non-executive directors, to review and monitor the financial reporting process and internal control systems[197]. - The audit committee reviewed the unaudited condensed consolidated financial statements for the period and confirmed compliance with applicable accounting standards[197]. - The company failed to comply with GEM listing rules regarding financial reporting due to travel restrictions in Taiwan and Vietnam related to COVID-19, impacting the audit of the financial statements for the year ended December 31, 2021[195]. Strategic Focus and Future Plans - The company has established a business structure focused on traditional funeral services and emerging biotechnology, with a long-term strategic emphasis on biotechnology[125]. - The company is primarily involved in stem cell applications and high-end biotechnology instruments, achieving substantial progress in these areas[125]. - The group plans to allocate more resources to support the development of its biotechnology business and actively seek suitable investment opportunities[159]. - The group is currently evaluating the impact of new accounting standards, with preliminary results indicating no significant effect on financial performance[32]. Shareholder Information - Mr. Xu Jianchun holds 220,475,000 shares, representing approximately 29.69% of the total issued shares[161]. - Dr. Xu Qiang and Mr. Sun Fei each hold 3,712,000 shares, accounting for 0.50% of the total issued shares[161]. - Mr. Xu Jianchun has a direct beneficial interest of 25.55% in Hong Kong Gaoqi and an additional 9.78% interest through HBT Limited[161]. - HBT Limited is registered in the British Virgin Islands and has two classes of shares, with different voting rights[161]. - Mr. Xu Jianchun controls 86.78% of the total voting rights in HBT Limited[161].

Financial Performance - The revenue for the three months ended March 31, 2022, was RMB 20,580,000, compared to RMB 18,961,000 for the same period in 2021, representing an increase of approximately 8.5%[4] - The gross profit for the same period was RMB 11,417,000, slightly up from RMB 11,123,000 in the previous year, indicating a growth of about 2.6%[4] - Operating profit decreased to RMB 2,593,000 from RMB 4,620,000 year-on-year, reflecting a decline of approximately 43.9%[4] - Profit before tax was RMB 2,093,000, down from RMB 3,975,000 in the prior year, marking a decrease of around 47.4%[4] - The net profit attributable to the owners of the company for the period was RMB 722,000, compared to RMB 2,657,000 in the same period last year, a decline of approximately 72.8%[15] - The company reported total comprehensive income of RMB (19,000) for the period, compared to RMB 3,787,000 in the previous year, indicating a significant drop[13] - Administrative expenses increased to RMB 6,505,000 from RMB 5,615,000, representing an increase of about 15.8%[4] - The company incurred financing costs of RMB 500,000, down from RMB 645,000, showing a reduction of approximately 22.5%[4] - Other income and gains netted a loss of RMB 1,548,000, compared to a gain of RMB 411,000 in the previous year, indicating a significant decline[4] - The company's basic earnings per share for the three months ended March 31, 2022, were RMB 0.10, a decrease of 72.2% from RMB 0.36 in the same period last year[50] Revenue Breakdown - Revenue from funeral services and cremation services was RMB 19,354,000, compared to RMB 18,210,000 in the previous year, reflecting an increase of about 6.3%[39] - The group recorded sales of cemetery plots and tombstones amounting to RMB 243,000, up from RMB 119,000 in the prior year, indicating a growth of approximately 104.2%[39] - Revenue from stem cell and immune cell consultation services was RMB 144,000, which was a new revenue stream introduced this year[39] - Revenue from external customers in China was RMB 19,354,000, an increase from RMB 18,210,000 in the previous year, showing a growth of about 6.3%[41] - Revenue from Taiwan was RMB 400,000, slightly up from RMB 396,000 in the previous year, indicating a growth of approximately 1%[41] - Revenue from Hong Kong increased to RMB 583,000 from RMB 236,000, representing a significant growth of about 146.2%[41] - Revenue from Vietnam rose to RMB 243,000 from RMB 119,000, marking an increase of approximately 104.2%[41] - The group’s revenue from Taiwan was approximately RMB 400,000, reflecting a year-on-year increase of about 1.0%[59] - Sales from cemetery services in Vietnam amounted to approximately RMB 243,000, representing a year-on-year increase of about 104.2% from RMB 119,000[60] Strategic Focus and Investments - The company continues to focus on expanding its services in China, Taiwan, and Hong Kong, as well as exploring opportunities in Vietnam for cemetery and related services[26] - The group has established a specialized investment platform focused on biotechnology, including biomedicine and life science instruments, to drive rapid business development[54] - The company plans to reduce investment in stem cell business in the short term due to regulatory constraints in mainland China[53] - The group aims to leverage resource advantages to expand its high-end biotechnology instrument business in response to the rapid development of the electronic microscope industry in mainland China[53] - The company is focusing on the development of biotechnology, with significant progress in sales of life science instruments[69] - The company plans to increase its investment in biotechnology and seek suitable investment opportunities to maximize returns for shareholders[72] Financial Management and Compliance - The company has invested a total of RMB 18,428,000 in joint ventures and construction projects as of March 31, 2022[65] - The company maintains a prudent financial management strategy to ensure adequate liquidity for operations and potential acquisitions[65] - The group has adopted new and revised accounting standards, which are not expected to have a significant impact on the financial statements[36] - The financial statements are prepared based on historical cost, with certain assets measured at fair value, including investment properties and financial assets[29] - The company faced delays in publishing its audited financial results for the year ended December 31, 2021, due to travel restrictions related to COVID-19, resulting in non-compliance with GEM listing rules[95] - The company published its preliminary unaudited full-year results for 2021 on March 30, 2022, following the guidelines provided for COVID-19 related delays[97] - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited consolidated financial statements for the period and confirmed compliance with applicable accounting standards[98] Shareholding and Governance - As of March 31, 2022, Mr. Xu holds 220,475,000 shares, representing approximately 29.69% of the total issued share capital of the company[76] - Mr. Xu has a direct beneficial interest of 25.55% in Hong Kong Gaoqi Biotechnology Co., Ltd. and a 9.78% interest in Houp Bio-Technology Limited[78] - HBT Limited has two classes of shares, with A shares having 30 votes per share and B shares having 1 vote per share[78] - Mr. Xu controls 94.07% of the A shares in HBT Limited, giving him a total voting power of 86.78% in HBT Limited[78] - Ms. Qiu holds 5.93% of the A shares and 10.74% of the B shares in HBT Limited, which are considered under Mr. Xu's interest[82] - No other directors or senior executives have disclosed any interests or short positions in the company's shares or related securities as of March 31, 2022[79] - Hong Kong Gaoqi holds 220,475,000 shares, also representing approximately 29.69% of the total issued share capital[81] - There are no significant transactions or contracts involving directors or their related entities during the reporting period[85] - The company has not entered into any management or administrative contracts for its business during the reporting period[88] - The company established a capital increase agreement and joint venture agreement on September 13, 2021, which was approved by shareholders on November 22, 2021[89] - The joint venture will engage in equity and/or securities investment business, while the partner will focus on technology development, consulting services, investment activities, and business management consulting[89]

Financial Performance - The revenue for the year ended December 31, 2021, was approximately RMB 72,864,000, representing a year-on-year increase of 6.6% compared to RMB 68,340,000 for the prior year[18]. - Revenue from the Taiwan market decreased to approximately RMB 1,450,000, a year-on-year decline of 32.5% from RMB 2,148,000 due to strict pandemic control measures[21]. - In Hong Kong, revenue from funeral arrangement and related consultancy services increased to approximately RMB 892,000, representing a year-on-year growth of 82.8% from RMB 488,000[21]. - The Group's revenue from the PRC market increased by 14.6% year-on-year to approximately RMB 70,294,000 from RMB 61,317,000 in the prior year[48]. - Revenue from funeral, cremation, and cemetery services in the PRC contributed approximately RMB 69,561,000, up from RMB 60,961,000 in the prior year[49]. - Revenue from Vietnam decreased by approximately 47.6% to RMB 228,000 from RMB 435,000 in the prior year[57]. - Gross profit for the year was approximately RMB 37,977,000, a year-on-year increase of 30.2%, with a gross profit margin of approximately 52.1% compared to 42.7% in the prior year[68]. - The increase in gross profit was mainly driven by the funeral services in China, which rebounded from the impact of COVID-19[68]. - The Group's funeral services in the PRC rebounded from the impact of COVID-19, benefiting from the recovery of economic activities[50]. - Loss attributable to the owners of the Company for the year was approximately RMB 9,872,000, compared to RMB 2,974,000 in the prior year, with loss per share of approximately RMB 1.33 cents[77]. Business Strategy and Focus - The Group's business pattern focuses on traditional funeral services and emerging biotechnology, with traditional funeral services accounting for a large proportion of the Group's business[18]. - The Group is focusing on biotechnology as a long-term business expansion strategy, particularly in stem cells and advanced biotechnical equipment[23]. - A specialized investment platform was established in December 2021 to promote the rapid development of the biotechnology business, focusing on biomedicine, medical healthcare, and life science instruments[25]. - The Group aims to allocate more resources to support the development of its biotechnology business while consolidating its traditional funeral services[26]. - The Group plans to reduce investments in the stem cell business in the short term due to the lack of large-scale development opportunities in Mainland China[23]. - The Group aims to expand its advanced biotechnical equipment business by leveraging opportunities in the rapidly developing electron microscope industry in Mainland China[42]. - The Group positions Zhongke Zhenhui as a specialized investment platform for biotechnology development, including biomedicine and medical healthcare[104]. - The Group will continue to monitor the impact of the COVID-19 pandemic on its financial position and operating results[79]. Economic Environment - China's GDP reached RMB 114.4 trillion in 2021, with a real GDP growth rate of 8.1%[17]. - The economic development in China is led by strategic emerging industries such as new energy, intelligent manufacturing, biomedicine, and semiconductors[17]. - The Chinese government established the Beijing Stock Exchange in November 2021 to expand financing channels for small and medium-sized enterprises, promoting innovative development in emerging industries[36]. - The ongoing COVID-19 pandemic continues to create uncertainty in the global economic environment, affecting customer spending and business operations[98]. - The strategic goals of supporting emerging industries and promoting high-quality economic development in China remain unchanged despite economic pressures[102]. Corporate Governance - The Company will review its corporate governance practices to ensure compliance with statutory requirements and the GEM Listing Rules[116]. - The Company emphasizes the importance of management reporting to the Board before making significant decisions or commitments[128]. - The Board has established three committees: Audit Committee, Remuneration Committee, and Nomination Committee, each with defined terms of reference[150]. - The Company has maintained compliance with GEM Listing Rules regarding Directors' securities transactions throughout the year[120]. - The Board consists of six Directors, demonstrating diversity in age, service length, educational background, and professional experience[198]. - The Nomination Committee believes the current Board composition meets measurable objectives for achieving diversity[200]. Human Resources - The Group employed approximately 171 employees as of December 31, 2021, a decrease from 179 employees in the prior year[91]. - The Group will implement various incentives to attract and retain top talents to improve operational conditions and enhance profitability[111]. - The attendance record for Directors at meetings indicates full participation from executive Directors[136]. Financial Position - As of December 31, 2021, the Group had cash and bank balances of approximately RMB 117,557,000, with current and non-current bank borrowings of approximately RMB 1,192,000 and RMB 4,812,000 respectively[77]. - The gearing ratio as of December 31, 2021, was approximately 2.3%, a slight decrease from 2.5% in the prior year[77]. - The Group did not use any financial instruments for hedging purposes during the year, maintaining a prudent financial management strategy[77]. - The Group's capital expenditure for property, plant, and equipment in 2021 amounted to approximately RMB 1,303,000, down from RMB 3,713,000 in the prior year[95]. - The Group's financial condition may be affected by changes in exchange rates of RMB against USD, NTD, HKD, and VTD[79].

THIRD QUARTERLY REPORT 2021 活出精彩 LIVE LIFE TO THE FULLEST 第三季度報告 2021 活出精彩 LIVE LIFE TO THE FULLEST 香港聯合交易所有限公司（「聯交所」）GEM之特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他 在聯交所上市的公司帶有較高投資風險。有意投資的人士應了解投資於該 分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 告共同及個別承擔全部責任。 事實致使本報告或其所載任何陳述產生誤導。 01 第三季 季度報告 2021 c_212380 (Sino-Life_3Q).indd 1 15/11/2021 10:55:42 等公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板 買賣的證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會 有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本報告全部或任何部 本報告乃遵照聯交所GEM ...

Financial Performance - The company's revenue for the six months ended June 30, 2021, was RMB 18,310,000, an increase of 12.2% compared to RMB 16,311,000 for the same period in 2020[8]. - The cost of sales and services for the same period was RMB 7,732,000, up from RMB 7,076,000, reflecting a 9.3% increase[8]. - The net profit attributable to the owners of the company was RMB (312,000), a decrease from RMB 2,997,000 in the previous year, indicating a significant decline in profitability[10]. - The total revenue for the funeral services and cremation services segment increased to RMB 35,521,000 in 2021 from RMB 27,535,000 in 2020, representing a growth of approximately 29%[33]. - The total profit for the reportable segments reached RMB 8,697,000 for the six months ended June 30, 2021, compared to RMB 3,193,000 for the same period in 2020, indicating an increase of approximately 172%[42]. - The company reported a total revenue of RMB 37,271,000 for the six months ended June 30, 2021, up from RMB 28,985,000 in the same period of 2020, reflecting a growth of about 29%[39]. - The company reported a pre-tax consolidated profit of RMB 4,711,000 for the six months ended June 30, 2021, compared to RMB 1,452,000 for the same period in 2020, an increase of approximately 224%[42]. - The income tax expense for the six months ended June 30, 2021, was RMB 2,896,000, significantly higher than RMB 940,000 in the same period of 2020[79]. Assets and Liabilities - The total assets as of June 30, 2021, amounted to RMB 153,519,000, compared to RMB 146,882,000 at the end of 2020, showing a growth of 4.4%[12]. - Cash and cash equivalents at the end of the reporting period were RMB 125,616,000, slightly up from RMB 123,674,000 at the beginning of the year[18]. - Trade receivables increased to RMB 1,291 thousand as of June 30, 2021, from RMB 996 thousand as of December 31, 2020, representing a growth of 29.5%[96]. - The net amount of trade receivables after expected credit loss provisions was RMB 914 thousand, up from RMB 619 thousand, indicating a 47.7% increase[96]. - The group’s financial liabilities measured at amortized cost decreased to RMB 14,847 thousand from RMB 16,876 thousand, a decline of 12.1%[103]. - The group’s capital commitments to joint ventures and associates were approximately RMB 8,700,000 as of June 30, 2021, up from RMB 6,500,000 as of December 31, 2020, indicating a growth of about 33.85%[110]. Expenses - Administrative expenses increased to RMB 8,149,000 from RMB 4,688,000, reflecting a rise of 73.5%[8]. - The sales cost for the period was approximately RMB 15,570,000, an increase of about 16.5% from RMB 13,361,000 in the previous period[132]. - Administrative expenses increased by approximately 26.9% to about RMB 13,764,000, accounting for 36.9% of revenue[134]. Cash Flow - The company reported a net cash inflow from operating activities of RMB 731,000, a significant decrease from RMB 9,156,000 in the same period last year[18]. - The group maintained a strong cash position with approximately RMB 125,616,000 in cash and bank balances as of June 30, 2021[136]. Market and Strategic Focus - The company plans to focus on market expansion and new product development to enhance future growth prospects[8]. - The group reported a significant focus on investment holding, primarily in funeral and related services in China, Taiwan, and Hong Kong, as well as cemetery sales in Vietnam and high-end biotech equipment sales in Hong Kong[20]. - The group plans to adhere to a diversified development strategy, allocating more resources to support the growth of its biotechnology business[149]. - The group aims to expand its investment business scale through equity and securities investment operations[149]. Compliance and Reporting - The unaudited interim financial statements were prepared in accordance with the Hong Kong Financial Reporting Standards, with no significant impact from the newly adopted standards during the reporting period[28]. - The financial statements are presented in Renminbi, with amounts rounded to the nearest thousand, indicating a structured approach to financial reporting[26]. - The management's application of accounting policies remains consistent with those used in the previous financial year, ensuring stability in financial reporting[24]. - The audit committee, consisting of three independent non-executive directors, has reviewed the unaudited condensed consolidated financial statements for the period and confirmed compliance with applicable accounting standards[175]. Employee and Management Compensation - The total remuneration for key management personnel for the six months ended June 30, 2021, was RMB 1,892,000, an increase of 25.14% from RMB 1,512,000 in the same period of 2020[111]. - The total remuneration for close relatives of key management personnel was RMB 128,000 for the six months ended June 30, 2021, compared to RMB 116,000 in the same period of 2020, reflecting a growth of approximately 10.34%[112]. Shareholder Information - As of June 30, 2021, Hong Kong Gaoqi Biotechnology Co., Ltd. held 220,475,000 shares, representing approximately 29.69% of the company's issued share capital[153]. - The company has adopted a new share option plan effective from April 22, 2021, which will remain valid for ten years, allowing for the issuance of up to 10% of the total issued shares as of the adoption date[161]. - The maximum number of shares that can be issued under the share option plan is 74,250,000 shares, representing 10% of the total issued shares as of the mid-term performance report date[164]. - No share options have been granted under the share option plan since its adoption date[165]. - The company did not purchase, sell, or redeem any of its listed securities during the reporting period[167].

Financial Performance - The company reported revenue of RMB 18,961,000 for the three months ended March 31, 2021, an increase of 49.7% compared to RMB 12,674,000 for the same period in 2020[8]. - Gross profit for the same period was RMB 11,123,000, resulting in a gross margin of approximately 58.7%, compared to RMB 6,389,000 and a gross margin of 50.4% in the previous year[8]. - Operating profit reached RMB 4,620,000, a significant improvement from an operating loss of RMB 1,326,000 in the prior year[8]. - The company achieved a profit before tax of RMB 3,975,000, compared to a loss before tax of RMB 2,064,000 in the same quarter of 2020[8]. - Net profit attributable to owners of the company was RMB 2,657,000, compared to a loss of RMB 2,109,000 in the previous year[8]. - The basic and diluted earnings per share for the quarter were RMB 0.36, compared to a loss per share of RMB 0.28 in the same quarter of 2020[8]. - The company reported total comprehensive income of RMB 3,787,000 for the quarter, compared to a total comprehensive loss of RMB 154,000 in the previous year[8]. - Total revenue for the period was approximately RMB 18,961,000, an increase of about 49.6% from RMB 12,674,000 in the previous period[41]. - Basic earnings per share for the period ended March 31, 2021, was RMB 0.36, compared to a loss of RMB 0.28 in the same period last year[32]. - The company reported a profit attributable to owners of RMB 2,657,000 for the period, compared to a loss of RMB 2,109,000 in the previous period[41]. Revenue Sources - The group's revenue from funeral services and cremation services for the three months ended March 31, 2021, was RMB 18,210,000, an increase of 51% compared to RMB 12,078,000 for the same period in 2020[22]. - Revenue from funeral arrangements and related consulting services was RMB 632,000, up 34% from RMB 470,000 in the previous year[22]. - Revenue from the Chinese market was approximately RMB 18,210,000, representing a significant increase of about 50.8% compared to RMB 12,078,000 in the previous period[37]. - Revenue from Taiwan increased by approximately 86.8% to RMB 396,000, while revenue from Hong Kong decreased by about 8.5% to RMB 236,000[39]. - Total revenue from external customers for the three months ended March 31, 2021, was RMB 18,961,000, compared to RMB 12,674,000 for the same period in 2020, reflecting a growth of 49%[25]. Operational Strategy - The company continues to focus on expanding its services in the funeral and related services sector in China, Taiwan, and Hong Kong[14]. - The company is also involved in the sale of cemetery plots and tombstones in Vietnam, as well as providing high-end biotechnology instruments and electronic products in Hong Kong and China[14]. - The company is committed to enhancing its operational efficiency and exploring new market opportunities to drive future growth[14]. - The company plans to allocate more resources to develop the emerging biotechnology industry while consolidating its traditional funeral service business[49]. - The biotechnology sector will integrate with new technologies such as artificial intelligence, big data, and the internet, focusing on innovations like medical robots and desktop electron microscopes[49]. - The company aims to enhance external cooperation through business licensing, equity investments, and mergers and acquisitions to improve operational conditions and optimize business structure[49]. - Various incentive measures will be implemented to attract and retain top talent and management personnel, contributing to the company's development[49]. Tax and Dividend Information - The group reported no tax provisions for Hong Kong profits tax during the period, as there were no taxable profits generated in Hong Kong[26]. - The group’s subsidiary in Chongqing, which benefits from a preferential tax rate of 15%, continued to apply this rate during the reporting period[28]. - The company did not recommend any dividend payments for the period, consistent with the previous period[31]. Challenges and Management - The company faced delays in financial reporting due to COVID-19 travel restrictions, impacting the audit of the financial statements for the year ended December 31, 2020[62]. - The company plans to continue monitoring the impact of COVID-19 on its financial performance and operations[44]. - The company maintains a prudent financial management strategy and aims to keep an appropriate level of liquidity to seize acquisition opportunities[46]. - The company’s operations in China have shown resilience against the impacts of COVID-19, with no significant adverse effects on its funeral and cremation services[47]. - The company established an audit committee to review and monitor financial reporting procedures and internal control systems[64]. - The audit committee consists of three independent non-executive directors, ensuring compliance with GEM listing rules[64]. Shareholder Information - The company reported a significant shareholder, Hong Kong Gaoqi Biotechnology Co., Ltd., holding 29.69% of the shares, equating to 220,475,000 shares[53]. - There were no significant contracts involving directors with a direct or indirect interest in the company's business during the reporting period[56]. - The company has not engaged in any arrangements that would allow directors or senior executives to acquire securities of the company or its affiliates during the reporting period[57].

8 於開發群島註冊成立的有限公司 股份代號:8296 JLLEST SINO LIFE GROUP LIMITED 中 國 生 命 集 團 有 限 公 司 2020 第三季度報告 H2( 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他 在聯交所上市的公司帶有較高投資風險。有意投資的人士應了解投資於該 等公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板 買賣之證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會 有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本報告全部或任何部 分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本報告的資料乃遵照聯交所GEM證券上市規則（「GEM上市規則」）而刊載， 旨在提供有關中國生命集團有限公司（「本公司」）的資料；本公司的董事（「董 事」）願就本報告的資料共同及個別地承擔全部責任。 各董事在作出一切合理查詢後，確認就其所知及所 ...

Financial Performance - Revenue for the six months ended June 30, 2020, was RMB 28,985,000, a decrease of 8.6% compared to RMB 31,705,000 for the same period in 2019[5] - Gross profit for the six months ended June 30, 2020, was RMB 15,624,000, representing a gross margin of 54.0%[5] - Operating profit for the six months ended June 30, 2020, was RMB 2,800,000, compared to RMB 1,429,000 for the same period in 2019[5] - Profit before tax for the six months ended June 30, 2020, was RMB 1,452,000, compared to RMB 201,000 for the same period in 2019[5] - Net profit for the six months ended June 30, 2020, was RMB 512,000, compared to a loss of RMB 372,000 for the same period in 2019[5] - Total comprehensive income for the six months ended June 30, 2020, was RMB 2,933,000, compared to RMB 622,000 for the same period in 2019[5] - Basic and diluted earnings per share for the six months ended June 30, 2020, were RMB 0.12, compared to RMB 0.03 for the same period in 2019[7] - The group reported a profit attributable to owners of RMB 2,997,000 for the three months ended June 30, 2020, compared to a loss of RMB (1,307,000) for the same period in 2019[78] - The company reported a profit attributable to shareholders of approximately RMB 888,000, compared to RMB 242,000 in the previous period, with earnings per share of RMB 0.12, up from RMB 0.03[128] Revenue Breakdown - Revenue from funeral services and cremation services for the six months ended June 30, 2020, was RMB 27,535,000, an increase of 6.9% from RMB 25,746,000 in the same period of 2019[33] - Revenue from funeral arrangement and related consultation services decreased significantly to RMB 1,119,000, down 79.7% from RMB 5,483,000 in the previous year[33] - Total revenue for the group during the period was RMB 28,985,000, a decrease of 9.1% compared to RMB 31,705,000 in the same period of 2019[33] - Revenue from the Chinese market was approximately RMB 27,606,000, a decrease of about 7.9% compared to the previous period's RMB 29,958,000[119] - Revenue from Taiwan was approximately RMB 798,000, a decrease of about 39.0% from RMB 1,308,000 in the previous period[122] - Revenue from Hong Kong increased by approximately 21.6% to RMB 321,000, compared to RMB 264,000 in the previous period[124] - Revenue from Vietnam increased by approximately 48.6% to RMB 260,000, compared to RMB 175,000 in the previous period[125] - The funeral, cremation, and cemetery services in China contributed approximately RMB 27,535,000, down from RMB 29,657,000 in the previous period, reflecting a decrease of about 7.2%[121] Cash Flow and Assets - For the six months ended June 30, 2020, the net cash generated from operating activities was RMB 9,156 thousand, compared to a net cash used of RMB 2,565 thousand in the same period of 2019[14] - The total cash and cash equivalents increased by RMB 5,277 thousand, reaching RMB 129,024 thousand as of June 30, 2020, compared to RMB 115,764 thousand at the end of June 2019[14] - Total assets as of June 30, 2020, were RMB 224,256,000, an increase from RMB 216,588,000 as of December 31, 2019[10] - Total liabilities as of June 30, 2020, were RMB 103,235,000, compared to RMB 99,901,000 as of December 31, 2019[10] - Net assets attributable to the owners of the company as of June 30, 2020, were RMB 120,582,000, an increase from RMB 117,649,000 as of December 31, 2019[10] - As of June 30, 2020, the group maintained a cash and bank balance of approximately RMB 129,024,000, an increase from RMB 119,216,000 as of December 31, 2019[129] Expenses and Costs - Employee costs, including director remuneration, totaled RMB 9,640,000 for the six months ended June 30, 2020, slightly up from RMB 9,583,000 in the previous year[66] - The financing costs for the six months ended June 30, 2020, were RMB 1,348,000, compared to RMB 1,228,000 in 2019, representing an increase of approximately 9.8%[66] - Selling expenses decreased by approximately 44.9% to about RMB 3,107,000 due to reduced sales activities following the outbreak of Covid-19[126] - Administrative expenses increased by approximately 14.3% to about RMB 10,844,000, representing 37.4% of revenue, compared to 29.9% in the previous period[126] - The cost of sales decreased to approximately RMB 13,361,000, down about 14.7% from RMB 15,658,000 in the previous period, attributed to reduced revenue across all business segments[126] Corporate Governance and Compliance - The financial statements are prepared in accordance with the applicable disclosure requirements of the GEM Listing Rules and comply with Hong Kong Financial Reporting Standards[18] - The financial statements have not been audited but have been reviewed by the company's audit committee[21] - The audit committee, composed of three independent non-executive directors, reviewed the unaudited consolidated financial statements for the period and confirmed compliance with applicable accounting standards[175] - The company emphasized the importance of high-quality governance and transparency to its shareholders[171] - The company has adopted a code of conduct for securities transactions by directors, ensuring compliance with strict trading standards[174] Impact of COVID-19 - The group has decided to suspend the elderly care services segment, which will no longer be reported separately and is classified as "unallocated"[34] - The group recorded approximately RMB 71,000 in revenue from the sale of stem cells and immune cells, a significant decrease from RMB 301,000 in the previous period[121] - The company faced challenges in financial reporting due to the impact of the COVID-19 pandemic on its operations in Taiwan and Vietnam[177] - The group will continue to monitor the impact of Covid-19 on its financial condition and operational performance while exploring opportunities for investment and mergers to optimize its business structure[140] Shareholder Information - Major shareholder Hong Kong Gaoqi holds 220,475,000 shares, representing 29.69% of the company's issued share capital[143] - The company has not disclosed any other individuals holding 5% or more of the shares as of June 30, 2020[145] - No significant contracts were reported where directors had a substantial interest during the period[146] Stock Options and Management - The stock option plan allows for a maximum of 74,250,000 shares to be issued, equivalent to 10% of the total shares issued as of the mid-term report date[153] - The stock option plan was approved for a duration of ten years, expiring on August 23, 2019, with no further options to be granted[151] - The company has not entered into any management contracts for significant parts of its business during the period[148] - The company reported a total of 48,232,000 stock options granted, with none exercised or canceled during the period[168] Future Outlook - The company plans to diversify its development strategy by actively engaging in the cell industry and enhancing cooperation with foreign biotechnology companies to improve operational performance[138] - The group is currently evaluating the impact of new accounting standards and amendments, with preliminary results indicating no significant impact on financial performance and position[31]

Business Performance - The Group recorded an increase in its funeral services business in the PRC compared to the prior year, benefiting from ongoing population aging and growth in purchasing power [18] - The sales of stem cell and immunocytes in the PRC contributed approximately RMB1,591,000 to this year's revenue [20] - The sales of advanced biotechnical equipment business in Hong Kong contributed approximately RMB3,263,000 during the year [20] - The Group recorded an increase in its funeral services business in the PRC, benefiting from rising consumption and ongoing population aging, compared to the prior year [40] - Revenue from stem cell and immunocyte sales in the PRC contributed approximately RMB 1,591,000 for the year [23] - Revenue from advanced biotechnical equipment sales in Hong Kong contributed approximately RMB 3,263,000 for the year [23] - The Group's total revenue for the year was approximately RMB66,610,000, representing an increase of approximately 6.3% compared to the prior year (RMB62,667,000) [61] - Revenue from the funeral business in mainland China increased slightly by approximately 1.9% to approximately RMB59,868,000 compared to the prior year [45] - Revenue from Taiwan decreased by 14.1% during the year, reflecting challenges in the market [51] - The Group recorded revenue of approximately RMB4,063,000 from Hong Kong, representing a fourfold increase compared to the prior year [52] - The Group's operation in Vietnam generated revenue of approximately RMB421,000, showing stability compared to the prior year (RMB335,000) [58] - The Group's elderly care services are also part of its revenue generation strategy, alongside funeral services and biotechnology sales [59] - The Group's revenue for the Year was approximately RMB66,610,000, representing an increase of about 6.3% compared to the prior year (RMB62,667,000) due to the new business segments in stem cell and immunocyte sales as well as advanced life science equipment sales [65] Strategic Development - The Company disposed of 40% of its interests in Bau Shan Life Science Technology Co., Ltd in April 2019 to focus on the biological technology industry development [19] - The Group's diverse development strategy in the cells industry has achieved substantial progress, including the sales of stem cell and immunocytes [20] - The Group's strategy aims to capitalize on the booming biological technology business, which is expected to enhance future performance [19] - The Company is actively positioning itself in the biotech industry, particularly in the cells sector, to leverage market opportunities [20] - The Group established a joint venture for cell cultivation research and development, owning 30% of the equity interests, marking a strategic move into the upstream of the cell industrial chain [25] - The Group plans to continue developing its cell business while consolidating new technologies and exploring quality projects for sustainable growth [35] - The Group aims to consolidate new technologies and research talents through collaborative investments, mergers, and restructuring [104] - The strategy includes exploring other promising projects to enhance the core cell industry and optimize business structure [104] Financial Performance - Cost of sales for the Year was approximately RMB34,568,000, slightly down from RMB34,778,000 in the prior year, with a decrease of approximately RMB3,936,000 attributed to the decline in the funeral services segment, offset by an increase of approximately RMB3,726,000 from the new stem cell and immunocyte sales [64] - Gross profit for the Year was approximately RMB32,042,000, with a gross profit margin increase to approximately 48.1% from 44.5% in the prior year, mainly due to effective cost control in the funeral services segment and higher margins from the new stem cell and immunocyte business [68] - Selling expenses increased by approximately 28.8% to approximately RMB7,169,000, accounting for about 10.8% of revenue, primarily due to the commencement of the stem cell and immunocyte sales [68] - Administrative expenses were approximately RMB28,273,000, representing about 42.4% of revenue, which remained relatively stable compared to the prior year [68] - The loss attributable to the owners of the Company for the Year was approximately RMB3,804,000, compared to a loss of approximately RMB8,352,000 in the Prior Year, resulting in a loss per share of approximately RMB0.51 cents (Prior Year: RMB1.12 cents) [72] - The Group's gross profit margin for funeral services was 50.1%, while the gross profit margin for stem cells and immunocytes business was 64.7% [61] Risk Management - The Group faces risks including economic slowdown, increased market competition, and reliance on skilled employees [81] - Financial risks include market risk, credit risk, and liquidity risk, as detailed in the consolidated financial statements [81] - The Group has established procedures for identifying, assessing, and managing significant risks [197] - Risk assessment involves evaluating identified risks based on management-established criteria and considering their potential impact and likelihood [197] - The Group prioritizes risks based on assessment results and determines risk management strategies and internal control procedures [197] - Continuous monitoring of risks is conducted, with regular reporting to management and the board on risk monitoring outcomes [197] - The Board is responsible for overseeing the risk management and internal control systems, ensuring they are effective [200] Corporate Governance - The Group emphasizes the importance of corporate governance and compliance with the Code on Corporate Governance Practices [108] - The Company has adopted a code of conduct for Directors' securities transactions, ensuring compliance with GEM Listing Rules [110] - The Board held a total of 9 meetings during the year, with attendance rates for executive directors ranging from 5/9 to 9/9 [123] - The roles of Chairman and CEO are held separately by Mr. Xu Jianchun and Mr. Liu Tien-Tsai, ensuring a clear division of responsibilities [128] - The Board complies with GEM Listing Rules, maintaining at least 3 independent non-executive Directors, representing at least one-third of the Board [129] - The Company has established an Audit Committee consisting of three independent non-executive Directors, complying with GEM Listing Rules 5.28 to 5.33 [138] - The Audit Committee reviewed the quarterly reports, half-yearly report, and annual report, focusing on compliance with accounting standards and GEM Listing Rules [142] - The Company has a Remuneration Committee composed of three independent non-executive Directors, which advises the Board on remuneration packages [143] - The Company has established a Board Diversity Policy, which is reviewed and considered regularly [154] - The Company adopted a Board Nomination Policy to ensure that Directors possess relevant background, experience, and knowledge critical to the Group's business [158] Employee Relations - The Group maintains good relationships with employees, customers, and suppliers, with no significant disputes reported during the year [90] - The Group employed approximately 188 employees as of 31 December 2019, an increase from 169 employees in the Prior Year [78] - All Directors participated in continuous professional development, ensuring their contributions to the Board remain informed and relevant [133] Environmental and Social Responsibility - The Group emphasizes environmental conservation through green office practices and encourages electronic record-keeping to reduce paper consumption [82] - There were no material breaches of laws and regulations affecting the Group's operations during the year [87]